home
د. فارس سعيد حمد ال منصور
أستاذ مساعد
كلية العلوم الطبية التطبيقية
قسم المختبرات الإكلينيكية
علم أمراض الخلايا والأنسجة
المؤهلات العلمية
Doctor of Philosophy in Mechanism of Cancer and Ageing, University of Leicester, United Kingdom, (2019-2023).
Master of Laboratory Medicine, Royal Melbourne Institute of Technology university, Australia, (2016-2017).
English for Academic Purposes at Advanced Level, RMIT English Worldwide – Melbourne Center, Australia, (2014-2015).
Bachelor of Medical Laboratory Sciences Najran University, Saudi Arabia, (2009-2013).
English for Academic Purposes at Advanced Level, RMIT English Worldwide – Melbourne Center, Australia, (2014-2015).
Bachelor of Medical Laboratory Sciences Najran University, Saudi Arabia, (2009-2013).
الخبرات
A lecturer of Histopathology at Medical Laboratory Sciences Department at Najran University and as Histopathological specialist at Najran University Hospital at the same time, 2023
A ssistant professor of Histopathology at Medical Laboratory Sciences Department at Najran University,2023
A teaching assistant at Medical Laboratory Sciences Department at Najran University, 2013-2019
A ssistant professor of Histopathology at Medical Laboratory Sciences Department at Najran University,2023
A teaching assistant at Medical Laboratory Sciences Department at Najran University, 2013-2019
التخصصات والمهارات
المهام الوظيفية
الدورات التدربية
المؤتمرات
Innovate Colloquium on Biotechnology & Industrial Revolution, Australia, 2017
Young International Senescence Association, UK, 2023
Al-Mansour F, Alraddadi A, He B, Saleh A, Poblocka M, Alzahrani W, Cowley S, Macip S. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic. Aging (Albany NY). 2023 Apr 4;15(7):2373.
Almasoudi HH, Nahari MH, Alhazmi AY, Almasabi SH, Al-Mansour FS, Hakami MA. Delineating Pixantrone Maleate’s adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation. Plos one. 2023 Dec 15;18(12):e0295714.
Almasoudi, H.H., Mashraqi, M.M., Alshamrani, S.A., Alharthi, A.A., Alsalmi, O., Nahari, M.H., Al-Mansour, F.S.H. and Alhazmi, A.Y.M., 2024. Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor. Pharmaceuticals, 17(2), p.208.
Al-Mansour FS, Almasoudi HH, Albarrati A. Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 Mar 22:1-9.
Almasabi SH, Almasoudi HH, Albargy H, Alabbas MM, Al-Mansour FS. Alternative use of droxidopa for treating cervical cancer: inhibiting transferase, cell cycle signalling, and transport proteins via multitarget docking, DFT, MD simulations, and binding free energy studies. Medical Oncology. 2025 May;42(5):1-23.
Alraddadi A, Smalley JP, Alzahrani W, Saleh A, Al?Mansour F, He B, Cao TH, Jayne S, Dyer M, Hodgkinson JT, Jones DJ. Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death. EJHaem. 2025 Aug;6(4):e70127.
Almasoudi HH, Nahari MH, Alhazmi AY, Almasabi SH, Al-Mansour FS, Hakami MA. Delineating Pixantrone Maleate’s adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation. Plos one. 2023 Dec 15;18(12):e0295714.
Almasoudi, H.H., Mashraqi, M.M., Alshamrani, S.A., Alharthi, A.A., Alsalmi, O., Nahari, M.H., Al-Mansour, F.S.H. and Alhazmi, A.Y.M., 2024. Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor. Pharmaceuticals, 17(2), p.208.
Al-Mansour FS, Almasoudi HH, Albarrati A. Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 Mar 22:1-9.
Almasabi SH, Almasoudi HH, Albargy H, Alabbas MM, Al-Mansour FS. Alternative use of droxidopa for treating cervical cancer: inhibiting transferase, cell cycle signalling, and transport proteins via multitarget docking, DFT, MD simulations, and binding free energy studies. Medical Oncology. 2025 May;42(5):1-23.
Alraddadi A, Smalley JP, Alzahrani W, Saleh A, Al?Mansour F, He B, Cao TH, Jayne S, Dyer M, Hodgkinson JT, Jones DJ. Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death. EJHaem. 2025 Aug;6(4):e70127.
(Histopathology -2 (Bachelor of Science in Clinical Laboratory
الساعات المكتبية
الوصف
| 8-9 | 9-10 | 10-11 | 11-12 | 12-1 | 1-2 | |
|---|---|---|---|---|---|---|
| الأحد Sunday |
ج-185 | ج-185 | ||||
| الاثنين Monday |
||||||
| الثلاثاء Tuesday |
||||||
| الأربعاء Wednesday |
ج-185 | ج-185 | ||||
| الخميس Thursday |